Loading…
BioXcel Therapeutics, Inc. is projected to decline to $0.7553 by 2027, a -11% move from its current price of $0.8476. BTAI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.8008 | $0.8463 | $0.8944 | -0.15% |
| Aug 6 | $0.7815 | $0.8451 | $0.9138 | -0.30% |
| Aug 7 | $0.7668 | $0.8438 | $0.9286 | -0.45% |
| Aug 8 | $0.7544 | $0.8426 | $0.9411 | -0.59% |
| Aug 9 | $0.7435 | $0.8413 | $0.952 | -0.74% |
| Aug 10 | $0.7337 | $0.8401 | $0.9619 | -0.89% |
| Aug 11 | $0.7247 | $0.8388 | $0.9709 | -1.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7247 | $0.8388 | $0.9709 | -1.04% |
| Week 2 | $0.675 | $0.8301 | $1.02 | -2.06% |
| Week 3 | $0.6376 | $0.8215 | $1.06 | -3.08% |
| Week 4 | $0.6068 | $0.813 | $1.09 | -4.09% |
| Week 5 | $0.5801 | $0.8045 | $1.12 | -5.08% |
| Week 6 | $0.5564 | $0.7962 | $1.14 | -6.07% |
| Week 7 | $0.5351 | $0.7879 | $1.16 | -7.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc.
was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BioXcel Therapeutics, Inc. trades under the symbol BTAI. The current price is $0.8475 and the market cap is $26.17M. Its rank is 4561. The stock’s price activity is accompanied by a technical picture that shows a bearish sentiment, with an RSI(14) of 40, and moving averages at SMA50 of $1.12 and SMA200 of $1.56.
The stock sits above no clear moat between support and resistance, with support at $0.802 and resistance at $1.41. The 30-day range spans from $0.5526 to $1.30. Annualized volatility is listed at 100%.
A major floor 54.4% below — a decisive break under it would weaken the trend.
The nearest floor, 6.4% below — buyers have tended to step in here.
The nearest ceiling, 66.4% above — a clean break opens room to run.
A major ceiling 91.2% above — clearing it would confirm fresh momentum.
Key BTAI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BTAI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.823 | Buy | $0.8198 | Buy |
| MA 10 | $0.8494 | Sell | $0.849 | Sell |
| MA 20 | $0.8842 | Sell | $0.9147 | Sell |
| MA 50 | $1.08 | Sell | $1.04 | Sell |
| MA 100 | $1.17 | Sell | $1.21 | Sell |
| MA 200 | $1.51 | Sell | $1.96 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.77 | Neutral |
| Stoch RSI (14) | 16.45 | Buy |
| CCI (20) | -88.74 | Neutral |
| Williams %R (14) | -93.67 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -12.36 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 6.33 | Buy |
| TRIX (15) | -1.16 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 30.95 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 0.79 | Buy |
| ADX (14) | 22.70 | Sell |
| ATR (14) | 0.04 | Info |
The near-term technical picture shows BEARISH sentiment with an RSI(14) of 40. The price is trading below the SMA50 of $1.12 and below the SMA200 of $1.56, indicating potential underperformance relative to these averages. Key levels to watch are support at $0.802 and resistance at $1.41.
The 30-day range is $0.5526 to $1.30, highlighting a broad band of recent movement.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.793 | $0.8476 | $1.02 | 0% | Neutral | |
| $0.5504 | $0.7553 | $1.12 | -11% | Neutral | |
| $0.453 | $0.6612 | $1.05 | -22% | Bearish | |
| $0.3944 | $0.6066 | $1.01 | -28% | Bearish | |
| $0.4959 | $0.7999 | $1.38 | -6% | Neutral | |
| $0.5763 | $0.9717 | $1.74 | +15% | Neutral | |
| $0.5641 | $0.9921 | $1.83 | +17% | Neutral | |
| $0.4698 | $0.8605 | $1.64 | +2% | Neutral | |
| $0.4244 | $0.8087 | $1.58 | -5% | Neutral | |
| $0.4468 | $0.885 | $1.77 | +4% | Neutral | |
| $0.5368 | $1.19 | $2.62 | +41% | Bullish | |
| $1.05 | $2.32 | $5.35 | +174% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.793 | $0.8476 | $1.03 | +0.00% |
| September 2026 | $0.6286 | $0.764 | $0.9689 | -9.86% |
| October 2026 | $0.6003 | $0.7399 | $0.9575 | -3.16% |
| November 2026 | $0.6219 | $0.7753 | $1.02 | +4.79% |
| December 2026 | $0.6098 | $0.7682 | $1.02 | -0.91% |
Click any year to see its month-by-month BTAI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
BioXcel Therapeutics, Inc.'s 2026 outlook centres on $0.8476, within a $0.793 to $1.02 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, BTAI could reach as high as $1.12, with a base case around $0.7553 and support toward $0.5504 — roughly -11% from $0.8476. Price action looks broadly range-bound.
Expect BTAI to range from $0.453 to $1.05 through 2028. The $0.6612 average target implies a -22% move from current prices. That is -12% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
The BTAI price prediction for 2029 points to an average of $0.6066 (low $0.3944, high $1.01) — a potential decline of -28% on today's $0.8476. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2030, BTAI is projected to trade between $0.4959 and $1.38, averaging $0.7999 — a potential decline of -6% from today's $0.8476. That is up +32% on the projected 2029 average. A consolidation phase looks the most probable path here.
BioXcel Therapeutics, Inc.'s 2031 outlook centres on $0.9717, within a $0.5763 to $1.74 range. That is up +21% on the projected 2030 average. That marks a +15% change versus current levels. Price action looks broadly range-bound.
By 2032, BTAI could reach as high as $1.83, with a base case around $0.9921 and support toward $0.5641 — roughly +17% from $0.8476. A consolidation phase looks the most probable path here.
Expect BTAI to range from $0.4698 to $1.64 through 2033. The $0.8605 average target implies a +2% move from current prices. That is -13% versus the projected 2032 average. Price action looks broadly range-bound.
The BTAI price prediction for 2034 points to an average of $0.8087 (low $0.4244, high $1.58) — a potential decline of -5% on today's $0.8476. A consolidation phase looks the most probable path here.
In 2035, BTAI is projected to trade between $0.4468 and $1.77, averaging $0.885 — a potential gain of +4% from today's $0.8476. That is up +9% on the projected 2034 average. Price action looks broadly range-bound.
BioXcel Therapeutics, Inc.'s 2040 outlook centres on $1.19, within a $0.5368 to $2.62 range. That is up +35% on the projected 2035 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, BTAI could reach as high as $5.35, with a base case around $2.32 and support toward $1.05 — roughly +174% from $0.8476. Momentum favours further upside here.
Investing $1,000 in BTAI today (≈ 1,179.801793 BTAI) could be worth
$2,741.77
+$1,741.77 (+174%) by 2050 · US Dollar
Based on the average projected BTAI price of $2.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BTAIwould be worth at today's price.
$1,000 invested in BTAI on Jul 31, 2025 (≈ 763.358812 BTAI) would be worth
$647.02
-$352.98 (-35.3%) today · 0.65× · US Dollar
Based on a BTAI entry price of $1.31 vs. today's $0.8476.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.848 | $999.53 | -0.0% |
| 1 month ago | $1.37 | $618.69 | -38.1% |
| 3 months ago | $1.2 | $706.33 | -29.4% |
| 6 months ago | $1.58 | $536.46 | -46.4% |
| 1 year ago | $1.31 | $647.02 | -35.3% |
| All time (5.0y) ago | $421.44 | $2.01 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BTAI forecast.
Our base-case forecast reaches $1.70 around 2050.
Implied market cap at $1.70: $52.49M
The multi-year forecast presents a mixed path with several down years before longer-term upside. In 2026 the Avg is $0.8475 with a min of $0.802 and a max of $1.01 and ROI of 0%, signaling neutral near-term expectations. The trajectory shows negative returns in 2027 (-10.9%), 2028 (-21.7%), and 2029 (-31.4%), reflecting downside risk in the mid-term.
By 2030 the Avg rises to $0.8184 with a max of $1.42 and a -3.4% ROI, followed by a return to positive returns thereafter (2031 Avg $0.9864, ROI 16.4%; 2032 Avg $0.9603, ROI 13.3%; 2033 Avg $0.8692, ROI 2.6%; 2034 Avg $0.8181, ROI -3.5%; 2035 Avg $0.8563, ROI 1%). The long horizon shows substantial upside later, with 2040 Avg $1.18 and ROI 39.4%, and 2050 Avg $2.30 with ROI 170.9%. The max values climb to $2.59 in 2040 and as high as $5.28 in 2050.
These are estimates and not guarantees, reflecting considerable year-to-year variability alongside potential long-term upside.
Tap a question to reveal the answer.
In 2030, the forecast lists min $0.5068, avg $0.8184, max $1.42 with ROI -3.4% and sentiment NEUTRAL.
Near-term forecasts show neutral to bearish signals (e.g., 2026 avg $0.8475; ROI 0%; 2027-2029 negative ROIs), but longer-term outlooks show bullish potential in 2040 (Avg $1.18; ROI 39.4%) and 2050 (Avg $2.30; ROI 170.9%), underscoring considerable uncertainty and variability.
Yes. The forecast shows max prices above $1 in several years, including 2026 max $1.01, 2030 max $1.42, 2031 max $1.77, 2032 max $1.78, and 2033 max $1.65.
Current price is $0.8475 and market cap is $26.17M.
2040: min $0.5317, avg $1.18, max $2.59; ROI 39.4%. 2050: min $1.03, avg $2.30, max $5.28; ROI 170.9%.
BioXcel Therapeutics, Inc. Community Discussion
0Share your BioXcel Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.